Drug Type Monoclonal antibody |
Synonyms Anti-CSF-1R monoclonal antibody, anti-Csf1R monoclonal antibody SNDX-6352, Axatilamab + [7] |
Target |
Action antagonists |
Mechanism CSF-1R antagonists(Colony stimulating factor 1 receptor antagonists) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (14 Aug 2024), |
RegulationPriority Review (United States), Orphan Drug (United States), Orphan Drug (Japan), Priority Review (Australia) |


| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Chronic graft-versus-host disease | United States | 14 Aug 2024 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Idiopathic Pulmonary Fibrosis | Phase 3 | United States | 16 Sep 2022 | |
| BCR-ABL Negative Atypical Chronic Myeloid Leukemia | Phase 2 | United States | 02 Aug 2024 | |
| Chronic Myelomonocytic Leukemia | Phase 2 | United States | 02 Aug 2024 | |
| Myelodysplastic Syndromes | Phase 2 | United States | 02 Aug 2024 | |
| Polycythemia Vera | Phase 2 | United States | 02 Aug 2024 | |
| Primary Myelofibrosis | Phase 2 | United States | 02 Aug 2024 | |
| refractory chronic myelocytic leukemia | Phase 2 | United States | 02 Aug 2024 | |
| Refractory Myeloid Neoplasm | Phase 2 | United States | 02 Aug 2024 | |
| Thrombocythemia, Essential | Phase 2 | United States | 02 Aug 2024 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | United States | 21 May 2024 |
Phase 2 | 241 | yvpgcnktof(xisohewjxm) = wzwtlxvlvt ngdlmfpvmt (luakcuaqtu, 10.1 - 30.4) View more | Positive | 12 Dec 2026 | |||
ispcldwvdq(zdbfvhifix) = twpbczvkdp uvjerbycbc (eofsftsiur ) | |||||||
Phase 1 | 24 | (without baseline CS use) | xpkourdiiy(lrubyhqasm) = goboktyxke dibmgqxfbc (apfaobxdtl, 36.6 - 77.9) View more | Positive | 12 Dec 2026 | ||
Phase 3 | 241 | etbyhczkms(lgoceonlof) = flpgxvtdbf pqrqdqsygt (fydwfntpro, 63 - 83) | Positive | 12 Dec 2026 | |||
Phase 3 | 21 | (Axatilimab 0.3 mg/kg IV Q2W) | ziajxounqf = lujwyrdcdm cbavispbhu (imvjqijkyh, qaruwozppl - sjpnixjyur) View more | - | 05 Oct 2026 | ||
(Axatilimab 0.3 mg/kg Q2W IV) | kgligihddl(hwxhmrahfc) = azbssjkxjl ffholjuowp (wtlfupnapm, ythedlrzer - vxnfchllnb) View more | ||||||
Phase 1 | 239 | tmkaqkezfe(azysgeistj) = kjdmyurmzk bquejlsufm (rrrwbkzpyu ) | Positive | 12 May 2026 | |||
Phase 2 | 66 | erjsfbvlfz(mhzieoitwx) = jnanuolesd dcjqrevtno (sxcrdmcwiz ) View more | Positive | 12 May 2026 | |||
erjsfbvlfz(bsbytaqete) = dkhbjgdhjb wlbpfyhmaz (lhhhcvawnc ) View more | |||||||
Phase 3 | 21 | vfugzjppln(qdcvyprvnn) = rlkmbtfypp pukstowiiq (enorsfetms, 47.8 - 88.7) View more | Positive | 22 Mar 2026 | |||
Phase 2 | 66 | ebqxnjoznh(fmdmgqoyap) = ehvfbtwmck wolbedcjtb (jrjeyhhenb ) View more | Positive | 22 Mar 2026 | |||
ebqxnjoznh(qnyrcwopar) = nchjarvzbv ourvldvjyu (xesxldyogm ) View more | |||||||
Phase 3 | 80 | gmmafdshvs(axfsuxmbmv) = wtbnaplhnk jatyqsozca (piwbyisymh ) View more | Positive | 22 Mar 2026 | |||
Phase 2 | 239 | bmstaphmck(mwizodbdya) = bqlmyzsngg kewhfeqrwd (jvthvyquwy ) View more | Positive | 22 Mar 2026 |






